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The South African Society of Psychiatrists (SASOP) 
Treatment Guidelines for Psychiatric Disorders have 
been developed in order to address the local need for 
guidelines in our unique clinical setting. The need for 
treatment guidelines has frequently been expressed by 
South African psychiatrists and other medical practitioners, as well 
as by other role players such as medical scheme and other funding 
body advisors and the pharmaceutical industry. While several well-
developed international treatment guidelines are readily accessible 
and are indeed extensively utilised in South Africa, they are not always 
applicable to our own circumstances. There are often important 
differences, not only regarding the availability of various psychotropic 
medications, but also in healthcare settings and availability of 
resources that need to be considered when selecting particular 
medications. For example, prescribing compounds that require 
regular monitoring such as lithium and clozapine may not always be 
feasible in certain rural settings in South Africa. 
It is important to point out that these Guidelines do not aim 
to provide a comprehensive review of all the pertinent literature 
comprising the evidence base, and as such, should be utilised in 
conjunction with other guidelines that do provide that kind of 
information. We advise readers to use these and other guidelines with a 
great deal of caution. Prescribing medication for psychiatric disorders 
comprises a major component of psychiatrists’, and indeed general 
practitioners’ function. It is therefore necessary for practitioners 
to maintain a high level of knowledge and expertise in clinical 
psychopharmacology, and to keep up-to-date with the ever-evolving 
‘evidence base’. However, it needs to be remembered that the evidence 
base in psychiatry is often difficult to interpret. Results of clinical 
trials are frequently difficult to generalise to clinical practice, and are 
often inconclusive, inconsistent or even conflicting. Methodological 
differences in aspects such as selection of patient samples, dosage and 
duration of treatment administered and outcome measures all make 
it difficult to interpret findings across studies. This means that ‘the 
evidence’ may be interpreted in different ways and there is a real risk 
that it can be selectively applied to support a particular point of view. 
This has been a point of criticism against the use of guidelines and 
evidence-based practice in psychiatry. At the end of the day it behoves 
practitioners to maintain an open and flexible mind, and most of all to 
apply sound clinical judgement and common sense when interpreting 
the available evidence.
These Guidelines do not cover all of the psychiatric disorders at this 
stage, although most of the important ones are covered. We envisage 
an ongoing process of updating and expanding the Guidelines 
regularly, as new drugs are introduced and as healthcare settings 
evolve. The chapters comprise a collection of systematically developed 
chapters in standardised format that attempt to provide evidence-
based recommendations for assessment and treatment of common 
psychiatric disorders. The aim is to provide guidelines that are of 
assistance to psychiatrists and other medical practitioners in clinical 
decision making. It is hoped that policy makers and administrators 
will also make use of them.
These SASOP Guidelines refer to the current private healthcare 
setting in South Africa. There are two important considerations 
here. First, the pending introduction of a National Health Insurance 
(NHI) in South Africa is likely to have an impact on the Guidelines. 
However, at present no details of the NHI are available and it has not 
been possible to take this into account in the current version. Second, 
a majority of the people in South Africa currently receive healthcare 
in the public sector and do not have access to many of the medications 
referred to in the SASOP Guidelines. This is clearly a shortcoming 
and an issue that needs to be addressed if the NHI is not going to be 
introduced in the near future. Nevertheless, we hope that the SASOP 
Guidelines will have some application in the public healthcare sector, 
and particularly that they may assist decision makers determine the 
most appropriate and cost-effective treatments in the public sector.
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The process. In 2009 the SASOP National Executive appointed Prof 
Robin Emsley to chair a Task-Team to develop the Guidelines. A team 
of experts was selected and several teleconference meetings were held. 
The experts were identified, based on both their academic and clinical 
experience, and they were invited to write one or two chapters. 
The authors were requested to write their chapters according to the 
following brief: 
• The Guidelines should be specific to South Africa. 
• We should aim at what is appropriate in a private practice setting – 
and what is realistic given our budgetary constraints. 
• As far as possible decisions should be evidence-based, and key 
references should be provided.
• The Guidelines should be clear, concise and user-friendly.
• Authors were encouraged to use the following documents as a point 
of departure: 
• Stein DJ, et al. Standard treatment guidelines for common mental 
health conditions, 2nd ed. South African Psychiatry Review 2007; 
10(2):106-119.
• The partly developed previous SASOP Guidelines, which were 
available on the SASOP website.
Each of the chapters was subjected to anonymous peer review by at 
least two reviewers, together with editorial review. Chapter drafts were 
revised according to these reviews. Finally, the chapters were edited 
and formatted according to a uniform style. These draft Guidelines 
were posted on the SASOP website (http://www.sasop.co.za/) and 
comment was invited. Finally, a SASOP workshop with national 
representation from both state-employed and private psychiatrists was 
held in George in April 2013 to finalise the document.
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It is recommended that the guidelines for bipolar disorder and 
major depressive disorder be considered in conjunction with the 
annexures for these guidelines (‘The management of psychiatric 
disorders; evidence-based and consensus treatment guidelines 
(including protocols and algorithms) for major depression 
and bipolar disorder; practice guideline for the private sector; 
Psychiatry Management Group (PsychMg)) that will be posted on 
the SASOP website (www.sasop.co.za).
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